普利制药前三季度净利润预增60%-70%

七印授权

VIVA3HB8YZ42TTT36M7VCE46ONHRCWK7URAQV2NKP0OONGO90

2019-10-10 13:05:43

article

D1F80F9886E4ABB0376D2B9FB1EA6BFB08319E6C280F6AF52AAEBDC8003C00E8

zh-CN

8CA3CC3F9F8343F14E5A8C352C76FFE87E9E7841

5038873

02636d79fc7c7cc37b9cb348037eec28743d030e5d570d0d69837a3587bed31880

e5153c413ad3d9443d09a60df638197b002352aa3654a4d6afbbc11029a7584d3ecbd277c8e8bf751682a1e8a4c65d2072755eb03dbe923198863c7dfdcc3e311c

{"type":"none"}

yuanben_5d9f2ca7217297.04096870

原本认证

https://www.yuanben.io/article/4efdc5ba-a9d4-4f0b-bd48-77110ed4571f

{"author":"上海证券报","authorization_pub_key":"03d634225939e0ea7567e7bfee2fa8784f72876cc8d95d47d72693d7ca8affd613"}